You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Tumour necrosis factor inhibitor monotherapy for CNS neurosarcoidosis

https://doi.org/10.1136/jnnp-2021-326267

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors JMG wrote the invited editorial commentary and is the guarantor.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests Research support to UCSF from Genentech/Roche for a clinical trial, consulting for Biogen, personal compensation for medical legal consulting.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles

    • Neuro-inflammation
      TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis
      Frédéric Hilezian Adil Maarouf Clemence Boutiere Audrey Rico Sarah Demortiere Philippe Kerschen Thomas Sene Caroline Bensa-Koscher Claire Giannesini Jean Capron Arsene Mekinian Jean-Philippe Camdessanché Géraldine Androdias Romain Marignier Nicolas Collongues Olivier Casez Catalina Coclitu Mathieu Vaillant Guillaume Mathey Jonathan Ciron Jean Pelletier Bertrand Audoin
      Journal of Neurology, Neurosurgery & Psychiatry 2021; 92 890-896 Published Online First: 08 Jun 2021. doi: 10.1136/jnnp-2020-325665